Literature DB >> 15545330

Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women.

Sara A Gardiner1, Mary F Morrison, P David Mozley, Lyn Harper Mozley, Colleen Brensinger, Warren Bilker, Andrew Newberg, Michelle Battistini.   

Abstract

OBJECTIVE: Authors investigated the association between estrogen replacement therapy (ERT) and dopamine transporter (DAT) availability in women.
METHODS: Thirteen postmenopausal women were administered ERT and underwent neuroimaging, using single-photon emission computed tomography (SPECT) and [99mTc]TRODAT-1, a radioligand that binds DAT. In this 6-week pilot study, subjects underwent SPECT before ERT, after 4 weeks of 0.625 mg/day of conjugated estrogens (CEE), and after an additional 2 weeks of 0.625 mg/day CEE plus 10 mg/day of medroxyprogesterone acetate. Specific uptake values (SUVs) of [99mTc]TRODAT-1 were calculated for the caudate and putamen.
RESULTS: When compared with baseline values, [99mTc]TRODAT-1 binding demonstrated a modest, but statistically significant, increase in the left anterior putamen after 4 weeks of CEE. After the 6-week ERT intervention, both the left and right anterior putamen demonstrated an increase in SUVs.
CONCLUSION: Short-term administration of ERT in postmenopausal women is associated with a modest increase in DAT in the putamen. These findings may further the understanding of how ERT is associated with improvement in Parkinson's disease and late-onset schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545330     DOI: 10.1176/appi.ajgp.12.6.621

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  20 in total

Review 1.  Aging of brain: role of estrogen.

Authors:  M K Thakur; P K Sharma
Journal:  Neurochem Res       Date:  2006-10-24       Impact factor: 3.996

2.  Neuroprotective effect of exogenous melatonin on dopaminergic neurons of the substantia nigra in ovariectomized rats.

Authors:  Fereshteh Mehraein; Reza Talebi; Behnamedin Jameie; Mohammad Taghi Joghataie; Zahra Madjd
Journal:  Iran Biomed J       Date:  2011

Review 3.  Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration.

Authors:  Rory D Spence; Rhonda R Voskuhl
Journal:  Front Neuroendocrinol       Date:  2011-12-24       Impact factor: 8.606

Review 4.  Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications.

Authors:  Darrell W Brann; Krishnan Dhandapani; Chandramohan Wakade; Virendra B Mahesh; Mohammad M Khan
Journal:  Steroids       Date:  2007-02-21       Impact factor: 2.668

5.  Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle.

Authors:  Susan E Best; Philip M Sarrel; Robert T Malison; Marc Laruelle; Sami S Zoghbi; Ronald M Baldwin; John P Seibyl; Robert B Innis; Christopher H van Dyck
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

6.  Lack of consistent sex differences in D-amphetamine-induced dopamine release measured with [18F]fallypride PET.

Authors:  Christopher T Smith; Linh C Dang; Leah L Burgess; Scott F Perkins; M Danica San Juan; Darcy K Smith; Ronald L Cowan; Nam T Le; Robert M Kessler; Gregory R Samanez-Larkin; David H Zald
Journal:  Psychopharmacology (Berl)       Date:  2018-10-22       Impact factor: 4.530

7.  Dopaminergic contributions to working memory-related brain activation in postmenopausal women.

Authors:  Julie A Dumas; Christopher G Filippi; Paul A Newhouse; Magdalena R Naylor
Journal:  Menopause       Date:  2017-02       Impact factor: 2.953

Review 8.  Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs.

Authors:  Jan Booij; Paul Kemp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-30       Impact factor: 9.236

9.  The roles of membrane estrogen receptor subtypes in modulating dopamine transporters in PC-12 cells.

Authors:  Rebecca A Alyea; Stephanie E Laurence; Sung H Kim; Benita S Katzenellenbogen; John A Katzenellenbogen; Cheryl S Watson
Journal:  J Neurochem       Date:  2008-05-19       Impact factor: 5.372

10.  Black cohosh and St. John's wort (GYNO-Plus) for climacteric symptoms.

Authors:  Da-Jung Chung; Hye-Yeon Kim; Ki-Hyun Park; Kyung-Ah Jeong; Sung-Ki Lee; Yu-Il Lee; Sung-Eun Hur; Min-Sun Cho; Byung Seok Lee; Sang Wook Bai; Cheong Mee Kim; Si Hyun Cho; Ju Youn Hwang; Joo Hyun Park
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.